Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 1,330 Shares of Stock

Posted by Joseph Casey on Nov 15th, 2024

RxSight, Inc. (NASDAQ:RXST – Get Free Report) insider Ilya Goldshleger sold 1,330 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $46.13, for a total value of $61,352.90. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at approximately $1,948,807.98. This represents a 3.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.79, for a total value of $154,349.00.
On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total value of $156,984.00.
On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total transaction of $154,008.00.
On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,529.45.
On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total value of $154,318.00.
On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00.
On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total transaction of $148,831.00.

RxSight Stock Performance

Shares of RXST stock traded down $0.49 during trading hours on Thursday, reaching $44.16. The company had a trading volume of 1,078,070 shares, compared to its average volume of 489,598. RxSight, Inc. has a 12-month low of $26.85 and a 12-month high of $66.54. The stock has a fifty day moving average of $50.48 and a 200-day moving average of $53.33. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -53.20 and a beta of 1.19.

Hedge Funds Weigh In On RxSight

Several institutional investors and hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. acquired a new position in shares of RxSight in the 1st quarter worth approximately $364,000. Swiss National Bank grew its stake in RxSight by 16.2% during the 1st quarter. Swiss National Bank now owns 53,100 shares of the company’s stock worth $2,739,000 after purchasing an additional 7,400 shares in the last quarter. ProShare Advisors LLC purchased a new stake in RxSight during the 1st quarter worth about $263,000. Entropy Technologies LP raised its position in RxSight by 67.2% in the 1st quarter. Entropy Technologies LP now owns 13,437 shares of the company’s stock valued at $693,000 after purchasing an additional 5,399 shares in the last quarter. Finally, M&G Plc purchased a new position in shares of RxSight in the 1st quarter valued at about $7,354,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RXST. Stifel Nicolaus decreased their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Oppenheimer reduced their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Jefferies Financial Group initiated coverage on RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Finally, Wells Fargo & Company decreased their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $61.63.

View Our Latest Analysis on RXST

RxSight Company Profile

(Get Free Report)

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.